Linn Woelber*1, Sabrina Mathey*1, Katharina Prieske*†, Sascha Kuerti*, Christoph Hillen*, Eike Burandt‡,
Anja Coym§, Volkmar Mueller*, Barbara Schmalfeldt*, Anna Jaeger*
Oncology Research, Vol.28, No.6, pp. 645-659, 2020, DOI:10.3727/096504020X16076861118243
Abstract Therapeutic options in recurrent or metastasized vulvar squamous cell cancer (VSCC) not amenable to radiotherapy or radical surgery are limited. Evidence for the use of targeted therapies is sparse. All patients with
VSCC treated at the Gynecological Cancer Center Hamburg-Eppendorf 2013–2019 were retrospectively evaluated for targeted therapeutic approaches. Furthermore, a MEDLINE, EMBASE, Web of Science, Scopus,
and OVID database search was performed using the terms: “vulvar cancer” AND “targeted therapy,” “erlotinib,” “EGFR,” “bevacizumab,” “VEGF,” “pembrolizumab,” or “immunotherapy.” Twelve of 291 patients
(4.1%) with VSCC received at least one targeted therapy at our institution. Previously, one or more platinumbased chemotherapy was… More >
Login
Register
